Multiple sourcing Framework Contracts to speed up the development of and access to innovative medical countermeasures Next Generation Therapeutics for Infectious Diseases
Planned
The competition has not been announced yet.
- Deadline
- May 27,Expired
- Agreement
- Framework agreement
- Estimated value
- €244Mover 9 years
Brief
The Health and Digital Executive Agency (HaDEA) is planning the procurement of services for the development of innovative Next Generation Therapeutics for Infectious Diseases, including pathogen-targeted and host-targeted therapeutics. This procurement aims to accelerate the development and access to medical countermeasures through a competitive, phased Pre-Commercial Procurement (PCP) approach. The total estimated value of the framework contracts is 244,000,000 EUR over 108 months.
Forsknings- og utviklingsvirksomhet og tilhørende konsulenttjenester
Custom Assessment Criteria
Get answers to your bid/no-bid criteria
Set them up once and Cobrief answers them in every tender
Will you bid?
The agent sets up the bid and writes the first draft. Free for 14 days.
Previous winners
Who are you up against?
The suppliers who have won similar contracts at Health and Digital Executive Agency (HaDEA) , HADEA - Health and Digital Executive Agency
From the notice
This call for tenders aims at speeding up the development of promising Next Generation Therapeutics for Infectious Diseases by adopting a competitive development in phases, under Pre-Commercial Procurement (PCP). The scope of the call is expected to cover the development of innovative therapeutics to treat viral infections, ARDS or sepsis resulting from infections, including pathogen-targeted therapeutics (but not small molecules or monoclonal antibodies) and host-targeted therapeutics, among which but not only direct-acting antivirals, indirect-acting antivirals and novel immune modulators. It may also cover innovative combinations therapies and products designed to be administered through alternative routes to IV. Broad spectrum therapeutics, pathogen-agnostic therapeutics and therapeutics that could reduce or counteract the emergence of viral resistance are of particular interest.
Contact
hadea-procurement@ec.europa.eu- Planning · Framework agreementType
- 73000000Main codeResearch and development services and related consultancy services
- 73100000Research and experimental development services